当前位置: 首页 >> 检索结果
7517. Diffuse Large B-Cell Lymphoma.
Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease, or both and require therapy. Despite the advanced stage at presentation in the majority of patients, more than 60% can be cured with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) immunochemotherapy (Fig. 1A). Patients with treatment failure after R-CHOP often have a poor outcome — in particular, those with disease that is refractory to frontline or subsequent therapies — although some patients can have a durable remission and be cured after secondary therapies. Over the past two decades, improved insights into large B-cell lymphomas, in terms of epidemiology, prognostic factors, and biologic heterogeneity, have led to a refinement of disease classification and the development of new therapeutic approaches.
7518. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
作者: Toni K Choueiri.;Thomas Powles.;Mauricio Burotto.;Bernard Escudier.;Maria T Bourlon.;Bogdan Zurawski.;Victor M Oyervides Juárez.;James J Hsieh.;Umberto Basso.;Amishi Y Shah.;Cristina Suárez.;Alketa Hamzaj.;Jeffrey C Goh.;Carlos Barrios.;Martin Richardet.;Camillo Porta.;Rubén Kowalyszyn.;Juan P Feregrino.;Jakub Żołnierek.;David Pook.;Elizabeth R Kessler.;Yoshihiko Tomita.;Ryuichi Mizuno.;Jens Bedke.;Joshua Zhang.;Matthew A Maurer.;Burcin Simsek.;Flavia Ejzykowicz.;Gisela M Schwab.;Andrea B Apolo.;Robert J Motzer.; .
来源: N Engl J Med. 2021年384卷9期829-841页
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.
7519. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
作者: Florence Wong.;S Chris Pappas.;Michael P Curry.;K Rajender Reddy.;Raymond A Rubin.;Michael K Porayko.;Stevan A Gonzalez.;Khalid Mumtaz.;Nicholas Lim.;Douglas A Simonetto.;Pratima Sharma.;Arun J Sanyal.;Marlyn J Mayo.;R Todd Frederick.;Shannon Escalante.;Khurram Jamil.; .
来源: N Engl J Med. 2021年384卷9期818-828页
The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe.
7520. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.
作者: Louise China.;Nick Freemantle.;Ewan Forrest.;Yiannis Kallis.;Stephen D Ryder.;Gavin Wright.;Andrew J Portal.;Natalia Becares Salles.;Derek W Gilroy.;Alastair O'Brien.; .
来源: N Engl J Med. 2021年384卷9期808-817页
Infection and increased systemic inflammation cause organ dysfunction and death in patients with decompensated cirrhosis. Preclinical studies provide support for an antiinflammatory role of albumin, but confirmatory large-scale clinical trials are lacking. Whether targeting a serum albumin level of 30 g per liter or greater in these patients with repeated daily infusions of 20% human albumin solution, as compared with standard care, would reduce the incidences of infection, kidney dysfunction, and death is unknown.
|